ELISA Automation Meets 21 CFR Part 11 Regulatory Compliance with Introduction of Agility® Integra from DYNEX

Chantilly, VA – DYNEX Technologies, a leading provider of laboratory diagnostic equipment, has unveiled the Agility^® Integra, a new fully automated ELISA system that brings speed, precision, and flexibility to the pharmaceutical and biotechnology markets. This high-throughput system features upgraded software capabilities for powerful results that comply with FDA Regulation 21 CFR Part 11.

Agility Integra’s open system takes ELISA testing to the next level, by allowing multiple immunoassays to run simultaneously. It guarantees data integrity and security with improved audit trails, chain of custody, lab information system connectivity, and secure networking.

Other advantages included enhanced import and export functionality, upgraded data encryption, and optimized reporting. This latest innovation represents the next step in DYNEX’s flagship automated microplate processor and offers unique value for highly regulated laboratory environments.

DYNEX CEO & President, Lisa A. Miller, describes the launch of Agility Integra as “a significant step forward for the company, and expanding its reach into the rapidly growing pharmaceutical and biotechnology sectors.” Ms. Miller believes that this specialized system “will enable DYNEX to have closer collaboration with key stakeholders and support global research and development efforts in pursuit of improved patient outcomes worldwide.”

With the market set to grow exponentially in the coming years, DYNEX is well positioned to become a key industry player.

DYNEX Vice President of Innovation, Rich Bahlmann, views the Agility Integra system as “a true game changer in the realm of clinical research and drug development, offering superior pipetting accuracy and state-of-the-art data protection.” Mr. Bahlmann is confident that the system “will propel clinical research and drug development initiatives forward, paving the way for groundbreaking advancements within the pharmaceutical and biotechnology field.”

The launch of Agility Integra comes as DYNEX Technologies continues to support the rapidly evolving clinical and research landscape. The new system underscores DYNEX’s focus on innovation and continued commitment to providing trusted technology that has the power to impact the lives of millions on a global scale.

For more information on Agility Integra, visit www.dynex.com/agility-integra.